Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | XPO1 | O14980 | 2/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6015303 | 1.00 | HDAC1 (0.46) | HDAC1HDAC2CA12CA1CA2 | |
| SCHEMBL6377578 | 0.84 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6185157 | 0.84 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2154529 | 0.83 | HDAC1 (0.52) | HDAC1HDAC2CA12CA1CA2 | |
| SCHEMBL1310629 | 0.83 | HDAC1 (0.52) | HDAC1HDAC2CA12CA1CA2 | |
| SCHEMBL6373690 | 0.81 | NPC1 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6373696 | 0.81 | NPC1 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31377124 | 0.81 | LMNA (0.56) | HDAC1HDAC2CA12CA7CA9 | |
| SCHEMBL6375776 | 0.81 | FDPS (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6375780 | 0.81 | FDPS (0.41) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439885-B1 | SIMPLIFIED SARCODICTYN DERIVATIVES AS ANTI-TUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2006-08-30 | — | — | EP | disclosed |
| US-20050153964-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| US-20050038112-A1 | Simplified sarcondictyn derivatives as anti-tumor agents | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2005-02-17 | — | — | US | disclosed |
| EP-1492787-A2 | (CONDENSED) PYRIMIDONE AND (CONDENSED) PYRIDONE COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| EP-1439885-A1 | SIMPLIFIED SARCODICTYN DERIVATIVES AS ANTI-TUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003087088-A2 | (CONDENSED) PYRIMIDONE AND (CONDENSED) PYRIDONE COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003024529-A1 | SIMPLIFIED SARCODICTYN DERIVATIVES AS ANTI-TUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153964-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | LYPLAL1, PLA2G12A, ENPP2 | HDAC1 3176/4885HDAC2 3333/4885CA12 4705/4885 |
| US-20050038112-A1 | Simplified sarcondictyn derivatives as anti-tumor agents | STOM, TTN, TNNC1 | HDAC1 2064/4885HDAC2 1309/4885CA12 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.